Stay updated with breaking news from Per Plotnikof. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
08 February 2024 ALK’s Board of Directors has approved the company’s 2023 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook. ALK expects...
08 February 2024ALK’s (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the company’s 2023 annual report. Following a robust performa...
ALK today announced that the European regulatory filing for ACARIZAX® in young children has been accepted for review by the relevant health authorities via a type II variation. The European...
The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension. ALK announced today that it has...
The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial...